These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 19060543)

  • 41. Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant.
    Rouce RH; Louis CU; Heslop HE
    Curr Opin Hematol; 2014 Nov; 21(6):476-81. PubMed ID: 25159713
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.
    Courtwright AM; Burkett P; Divo M; Keller S; Rosas IO; Trindade A; Mody GN; Singh SK; El-Chemaly S; Camp PC; Goldberg HJ; Mallidi HR
    Ann Thorac Surg; 2018 Feb; 105(2):441-447. PubMed ID: 29223419
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment for Epstein-Barr virus-associated PTLD.
    Gross TG
    Herpes; 2009 Jan; 15(3):64-7. PubMed ID: 19306606
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interferon-alpha and its effects on post-transplant lymphoproliferative disorders.
    Faro A
    Springer Semin Immunopathol; 1998; 20(3-4):425-36. PubMed ID: 9870255
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.
    Sprangers B; Riella LV; Dierickx D
    Am J Kidney Dis; 2021 Aug; 78(2):272-281. PubMed ID: 33774079
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
    Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorder.
    Hatton O; Martinez OM; Esquivel CO
    Pediatr Transplant; 2012 May; 16(3):220-9. PubMed ID: 22353174
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting.
    Paya CV; Fung JJ; Nalesnik MA; Kieff E; Green M; Gores G; Habermann TM; Wiesner PH; Swinnen JL; Woodle ES; Bromberg JS
    Transplantation; 1999 Nov; 68(10):1517-25. PubMed ID: 10589949
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus.
    Sindhi R; Webber S; Venkataramanan R; McGhee W; Phillips S; Smith A; Baird C; Iurlano K; Mazariegos G; Cooperstone B; Holt DW; Zeevi A; Fung JJ; Reyes J
    Transplantation; 2001 Sep; 72(5):851-5. PubMed ID: 11571449
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biomarkers for PTLD diagnosis and therapies.
    Martinez OM
    Pediatr Nephrol; 2020 Jul; 35(7):1173-1181. PubMed ID: 31240394
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The biology of Epstein-Barr virus in post-transplant lymphoproliferative disease.
    Hsieh WS; Lemas MV; Ambinder RF
    Transpl Infect Dis; 1999 Sep; 1(3):204-12. PubMed ID: 11428990
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients.
    Riddler SA; Breinig MC; McKnight JL
    Blood; 1994 Aug; 84(3):972-84. PubMed ID: 8043879
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advanced therapeutic and prophylactic strategies for Epstein-Barr virus infection in immunocompromised patients.
    Okano M; Gross TG
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):403-13. PubMed ID: 17547505
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
    Kogan-Liberman D; Burroughs M; Emre S; Moscona A; Shneider BL
    J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):445-9. PubMed ID: 11698761
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Simian virus 40 in posttransplant lymphoproliferative disorders.
    Vilchez RA; Jauregui MP; Hsi ED; Novoa-Takara L; Chang CC
    Hum Pathol; 2006 Sep; 37(9):1130-6. PubMed ID: 16938517
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
    Davis JE; Moss DJ
    Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.
    San-Juan R; Manuel O; Hirsch HH; Fernández-Ruiz M; López-Medrano F; Comoli P; Caillard S; Grossi P; Aguado JM; ;
    Clin Microbiol Infect; 2015 Jun; 21(6):604.e1-9. PubMed ID: 25686696
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical and virologic outcomes in high-risk adult Epstein-Barr virus mismatched organ transplant recipients.
    Kumar D; Patil N; Husain S; Chaparro C; Bhat M; Kim SJ; Humar A
    Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28489256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.